Michel Mikhail - Net Worth and Insider Trading

Michel Mikhail Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michel Mikhail owns 1 companies in total, including Navidea Biopharmaceuticals Inc (NAVB) .

Click here to see the complete history of Michel Mikhail’s form 4 insider trades.

Insider Ownership Summary of Michel Mikhail

Ticker Comapny Transaction Date Type of Owner
NAVB Navidea Biopharmaceuticals Inc 2021-10-01 Chief Regulatory Officer

Michel Mikhail Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Michel Mikhail Ownership Network

Ownership Network List of Michel Mikhail

No Data

Ownership Network Relation of Michel Mikhail


Michel Mikhail Owned Company Details

What does Navidea Biopharmaceuticals Inc do?

Who are the key executives at Navidea Biopharmaceuticals Inc?

Michel Mikhail is the Chief Regulatory Officer of Navidea Biopharmaceuticals Inc. Other key executives at Navidea Biopharmaceuticals Inc include Chief Financial Officer Craig Dais , director & 10 percent owner Scott John K Jr. , and Chief Business Officer Joel H. Kaufman .

Navidea Biopharmaceuticals Inc (NAVB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Navidea Biopharmaceuticals Inc (NAVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Navidea Biopharmaceuticals Inc (NAVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Navidea Biopharmaceuticals Inc (NAVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Navidea Biopharmaceuticals Inc Insider Transactions

No Available Data

Michel Mikhail Mailing Address

Above is the net worth, insider trading, and ownership report for Michel Mikhail. You might contact Michel Mikhail via mailing address: 4995 Bradenton Ave, Suite 240, Dublin Oh 43017.

Discussions on Michel Mikhail

No discussions yet.